drugset
drugset / Trial / NCT02957682

Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo

NCT02957682 ↗

Phase 4 Completed 2176 enrolled Regeneron Pharmaceuticals Sanofi · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The main purpose of this study is to evaluate the effect on mental state (known as "neurocognitive function") with use of Praluent.

Timeline

Start
2016-11-02
Primary completion
2020-03-05
Completion
2020-03-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Alirocumab Monoclonal antibody — Subcutaneous

Indications

hyperlipoproteinemia